Increased Serum 25(OH)D<sub>3</sub> Levels in Post-Menopausal Japanese Women with Osteoporosis after 3-Year Bisphosphonate Treatment-Reference-Cited by-同舟云学术

Increased Serum 25(OH)D₃ Levels in Post-Menopausal Japanese Women with Osteoporosis after 3-Year Bisphosphonate Treatment

Published:2017 Issue:3 Volume:242 Page:241-246
ISSN:0040-8727
Container-title:The Tohoku Journal of Experimental Medicine
language:en
Short-container-title:Tohoku J. Exp. Med.

Author:

Nakamura Yukio¹,Uchiyama Shigeharu¹,Kamimura Mikio²,Ikegami Shota¹,Komatsu Masatoshi¹,Kato Hiroyuki¹

Affiliation:

1. Department of Orthopaedic Surgery, Shinshu University

2. Center of Osteoporosis and Spinal Disorders, Kamimura Orthopaedic Clinic

Publisher

Tohoku University Medical Press

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://www.jstage.jst.go.jp/article/tjem/242/3/242_241/_pdf

Reference23 articles.

1. Antoniucci, D.M., Vittinghoff, E., Palermo, L., Black, D.M. & Sellmeyer, D.E. (2009) Vitamin D insufficiency does not affect response of bone mineral density to alendronate. Osteoporos. Int., 20, 1259-1266.

2. Bekker, P.J., Holloway, D.L., Rasmussen, A.S., Murphy, R., Martin, S.W., Leese, P.T., Holmes, G.B., Dunstan, C.R. & DePaoli, A.M. (2004) A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J. Bone Miner. Res., 19, 1059-1066.

3. Bone, H.G., Hosking, D., Devogelaer, J.P., Tucci, J.R., Emkey, R.D., Tonino, R.P., Rodriguez-Portales, J.A., Downs, R.W., Gupta, J., Santora, A.C. & Liberman, U.A.; Alendronate Phase III Osteoporosis Treatment Study Group (2004) Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med., 350, 1189-1199.

4. Brincat, M., Gambin, J., Brincat, M. & Calleja-Agius, J. (2015) The role of vitamin D in osteoporosis. Maturitas, 80, 329-332.

5. Chung, H.Y., Chin, S.O., Kang, M.I., Koh, J.M., Moon, S.H., Yoon, B.K., Yoon, H.K., Chung, Y.S. & Park, H.M. (2011) Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis. Clin. Endocrinol. (Oxf), 74, 699-704.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: A prospective cohort study;Bone Reports;2021-06

2. Unexpected rapid increase in bone mineral density by bisphosphonate therapy after multiple spinal fractures: a case report;Journal of Medical Case Reports;2019-09-13

3. Additive effects of eldecalcitol in poorly responding long-term bisphosphonate treatment for osteoporosis;Osteoporosis and Sarcopenia;2019-06

4. Calcium and vitamin D supplementation with 3-year denosumab treatment is beneficial to enhance bone mineral density in postmenopausal patients with osteoporosis and rheumatoid arthritis;Therapeutics and Clinical Risk Management;2018-12

5. Factors associated with decreasing serum 25(OH)D among Japanese patients with rheumatoid arthritis: Results from the IORRA cohort study;Modern Rheumatology;2018-07-11